BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Tau Therapeutics, LLC Completes Phase 1 Clinical Trial of Mibefradil for Use in Oncology


1/3/2013 9:13:25 AM

CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--JPMorgan Healthcare Conference Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for use in the treatment of solid tumors, announced today that it has completed a Phase 1 trial in normal healthy volunteers with its novel repositioned drug for use in cancer therapy, mibefradil. The 30-patient dose escalation trial evaluated the detailed pharmacokinetics of mibefradil administered four times a day and confirmed its safe dose levels for use in a Phase 1b trial. Tau concluded the trial prior to reaching a dose limiting toxicity when pharmacokinetic data demonstrated that the study reached plasma concentrations of mibefradil in humans equal to the concentrations found to be effective in pre-clinical xenograft models.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES